Pancreatic cancer has a current five-year survival rates of less than 10%. Current standard treatment is combination chemotherapy with FOLFIRINOX or Gemcitabine + Abraxane. The glycolic and mitochondrial metabolism is aberrant in pancreatic cancer and translates into chemo-resistance. Inhibition of glutamine metabolism can potentially synergize with therapies that increase intracellular reactive oxygen species such as chemotherapy. The lipoate derivative CPI-613 is a first-in-class agent that targets mitochondrial metabolism. Whether this novel anti-cancer agent could enhance the efficacy of FOLFIRINOX is unknown.
